Immunovant
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $1,500 | $0 |
Gross Profit | -80 | 1,436 | -58 | |
EBITDA | -115,654 | -94,201 | -80,815 | -61,495 |
EBIT | -115,743 | -94,281 | -80,879 | -61,553 |
Net Income | -109,119 | -87,150 | -75,319 | -51,418 |
Net Change In Cash | 0 | 0 | 1,500 | 0 |
Free Cash Flow | -88,843 | -76,381 | -59,849 | -47,229 |
Cash | 472,941 | 560,005 | 635,365 | 690,937 |
Basic Shares | 146,468 | 146,085 | 145,355 | 144,523 |
Annual Financials
| Values in thousands | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -231 | -1,324 | -1,232 | -998 |
EBITDA | -269,978 | -209,627 | -155,582 | -106,791 |
EBIT | -270,209 | -210,951 | -156,814 | -107,789 |
Net Income | -259,336 | -210,960 | -156,730 | -107,431 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Cost of Revenue | -117,505 | 93,763 | 299,575 | |
Free Cash Flow | -214,587 | -188,390 | -106,366 | -83,537 |
Cash | 635,365 | 376,532 | 493,817 | 400,146 |
Basic Shares | 138,100 | 123,075 | 109,679 | 87,756 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.74 |
2024-06-30 | -$0.60 |
2024-03-31 | -$0.52 |
2023-12-31 | -$0.36 |
